• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 4 filed by Director Conaway Samuel

    3/18/25 8:18:31 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care
    Get the next $GUTS alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Conaway Samuel

    (Last) (First) (Middle)
    3 VAN DE GRAAFF DRIVE
    SUITE 200

    (Street)
    BURLINGTON MA 01803

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    FRACTYL HEALTH, INC. [ GUTS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    03/17/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 0(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On March 17, 2025, a Form 4 was mistakenly filed on behalf of the Reporting Person reporting a purchase of 8,550 shares of common stock that did not in fact occur. As of March 13, 2025 and the date hereof, the Reporting Person does not own any shares of common stock.
    /s/ Lisa A. Davidson, Attorney-in-fact 03/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GUTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GUTS

    DatePrice TargetRatingAnalyst
    1/30/2026$2.00Overweight → Equal-Weight
    Morgan Stanley
    9/15/2025$9.00Buy
    H.C. Wainwright
    8/28/2025$3.60Buy
    Ladenburg Thalmann
    2/28/2024Outperform
    Evercore ISI
    2/27/2024$18.00Overweight
    Morgan Stanley
    2/27/2024$26.00Buy
    BofA Securities
    More analyst ratings

    $GUTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Smith Weber Lara

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    1/14/26 4:30:03 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Smith Weber Lara

    3 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    1/14/26 4:15:03 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President, Chief Product Off. Caplan Jay David

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/17/25 6:00:05 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

    Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita's potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026 Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying

    1/29/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

    BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes ("T2D"), today announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Ms. Smith Weber will oversee finance, accounting, and investor relations; and will serve as a key strategic partner to the Company's executive leadership team and Board of Directors. Ms. Smith Weber brings more than 20 years of financial leadership experience across medtech, biotech, and other growth-oriented industries. She has a str

    1/6/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

    Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approximately $85.6 million in cash and cash equivalents on hand, supporting execution across planned 2026 milestones Received gross proceeds of $23.0 million from exercises of Tranche A warrants from August 2025 financing, with cash runway into early 2027 BURLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D)

    1/5/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    SEC Filings

    View All

    Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

    1/29/26 8:00:35 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Fractyl Health Inc.

    S-8 - FRACTYL HEALTH, INC. (0001572616) (Filer)

    1/13/26 6:35:56 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

    1/6/26 7:05:26 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Rajagopalan Harith bought $19,999 worth of shares (10,416 units at $1.92), increasing direct ownership by 2% to 501,745 units (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/8/25 7:05:03 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 7:57:09 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 4:50:44 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fractyl Health downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Fractyl Health from Overweight to Equal-Weight and set a new price target of $2.00

    1/30/26 6:42:49 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Fractyl Health with a new price target

    H.C. Wainwright initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $9.00

    9/15/25 8:08:19 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on Fractyl Health with a new price target

    Ladenburg Thalmann initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $3.60

    8/28/25 8:09:13 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Financials

    Live finance-specific insights

    View All

    Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

    Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita's potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026 Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying

    1/29/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

    BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November 12, 2025, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a metabolic therapeutics company f

    11/5/25 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

    BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the conference call and presentatio

    8/6/25 4:05:00 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Leadership Updates

    Live Leadership Updates

    View All

    Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

    BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he

    4/2/24 8:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

    LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's

    2/20/24 8:38:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/14/24 4:30:50 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/13/24 5:17:27 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - Fractyl Health, Inc. (0001572616) (Subject)

    2/16/24 9:43:25 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care